Hinova Pharmaceuticals Inc. (SHA:688302)

China flag China · Delayed Price · Currency is CNY
50.86
+1.66 (3.37%)
At close: Jul 4, 2025, 2:57 PM CST
104.18%
Market Cap 5.04B
Revenue (ttm) 366.84K
Net Income (ttm) -184.38M
Shares Out 99.02M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,894,116
Average Volume 3,943,274
Open 48.89
Previous Close 49.20
Day's Range 48.44 - 52.00
52-Week Range 23.14 - 60.32
Beta 0.06
RSI 54.65
Earnings Date Aug 14, 2025

About Hinova Pharmaceuticals

Hinova Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and production of therapeutics for cancers and metabolic syndromes. It develops drugs based on proteolysis targeting chimera and deuteration technology. The company’s products pipeline includes HC-1119, a product in phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product in phase II clinical trials to treat various late... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 174
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688302
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.